Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-01 Monotherapy and Combination with Everolimus in Advanced HCC
NCT06994572Phase 1Not yet recruiting
- Sponsor
- Captor Therapeutics
- Start
- May 2025
- Primary completion
- Apr 2029
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment), Molecular Glues
01
Overview
Phase 1, open-label trial of CT-01 in hepatocellular carcinoma (HCC) (4 arms), sponsored by Captor Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 12 months and Maximum Tolerated Dose at 12 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
CT-01
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06994572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994572.